Strategies for developing effective radioimmunotherapy for solid tumors

Gerald L Denardo, Robert T O'Donnell, Linda A. Kroger, Carol M Richman, Desiree S. Goldstein, Sui Shen, Sally J. DeNardo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Single-agent radioimmunotherapy (RIT) has proven efficacy as a treatment for hematological malignancies, particularly non-Hodgkin's lymphoma. Although promising, RIT has been less effective for solid tumors, in part because they are less radiosensitive. Bone marrow transplantation permits the administration of larger radiopharmaceutical doses, but the results of bone marrow transplantation-supported RIT for solid tumors have been marginal. The purpose of this publication is to provide an overview of promising RIT strategies for solid tumors. It is apparent that combination therapy is required, but optimization of the radiopharmaceutical should be the first step. Metallic radionuclides provide higher tumor radiation doses but not necessarily an improved therapeutic index, that is, the ratio of tumor:normal tissue radiation doses. Biodegradable peptide linkers between the chelated metal and the antibody improve the therapeutic index. Further improvements depend on identification of synergistic therapies which recognize that: (a) continuous, low-dose radionuclide therapy acts through apoptosis; and (b) apoptosis is often blocked because most tumors have ineffective p53 and increased Bcl-2. Taxanes are particularly attractive as synergistic agents for RIT because they induce cell cycle arrest in the radiosensitive G2-M phase and p53-independent apoptosis. Optimal sequence and timing for combined modality RIT are critical to achieve synergy. Data from preclinical and clinical studies will be reviewed to illustrate the potential of these strategies.

Original languageEnglish (US)
JournalClinical Cancer Research
Volume5
Issue number10 SUPPL.
StatePublished - Oct 1999

Fingerprint

Radioimmunotherapy
Neoplasms
Radiopharmaceuticals
Apoptosis
Bone Marrow Transplantation
Radioisotopes
Therapeutics
Radiation
Taxoids
G2 Phase
Hematologic Neoplasms
Cell Cycle Checkpoints
Cell Division
Non-Hodgkin's Lymphoma
Metals
Peptides
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Strategies for developing effective radioimmunotherapy for solid tumors. / Denardo, Gerald L; O'Donnell, Robert T; Kroger, Linda A.; Richman, Carol M; Goldstein, Desiree S.; Shen, Sui; DeNardo, Sally J.

In: Clinical Cancer Research, Vol. 5, No. 10 SUPPL., 10.1999.

Research output: Contribution to journalArticle

Denardo, Gerald L ; O'Donnell, Robert T ; Kroger, Linda A. ; Richman, Carol M ; Goldstein, Desiree S. ; Shen, Sui ; DeNardo, Sally J. / Strategies for developing effective radioimmunotherapy for solid tumors. In: Clinical Cancer Research. 1999 ; Vol. 5, No. 10 SUPPL.
@article{dfb27d1aa765447c9b92a20473de6877,
title = "Strategies for developing effective radioimmunotherapy for solid tumors",
abstract = "Single-agent radioimmunotherapy (RIT) has proven efficacy as a treatment for hematological malignancies, particularly non-Hodgkin's lymphoma. Although promising, RIT has been less effective for solid tumors, in part because they are less radiosensitive. Bone marrow transplantation permits the administration of larger radiopharmaceutical doses, but the results of bone marrow transplantation-supported RIT for solid tumors have been marginal. The purpose of this publication is to provide an overview of promising RIT strategies for solid tumors. It is apparent that combination therapy is required, but optimization of the radiopharmaceutical should be the first step. Metallic radionuclides provide higher tumor radiation doses but not necessarily an improved therapeutic index, that is, the ratio of tumor:normal tissue radiation doses. Biodegradable peptide linkers between the chelated metal and the antibody improve the therapeutic index. Further improvements depend on identification of synergistic therapies which recognize that: (a) continuous, low-dose radionuclide therapy acts through apoptosis; and (b) apoptosis is often blocked because most tumors have ineffective p53 and increased Bcl-2. Taxanes are particularly attractive as synergistic agents for RIT because they induce cell cycle arrest in the radiosensitive G2-M phase and p53-independent apoptosis. Optimal sequence and timing for combined modality RIT are critical to achieve synergy. Data from preclinical and clinical studies will be reviewed to illustrate the potential of these strategies.",
author = "Denardo, {Gerald L} and O'Donnell, {Robert T} and Kroger, {Linda A.} and Richman, {Carol M} and Goldstein, {Desiree S.} and Sui Shen and DeNardo, {Sally J.}",
year = "1999",
month = "10",
language = "English (US)",
volume = "5",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "10 SUPPL.",

}

TY - JOUR

T1 - Strategies for developing effective radioimmunotherapy for solid tumors

AU - Denardo, Gerald L

AU - O'Donnell, Robert T

AU - Kroger, Linda A.

AU - Richman, Carol M

AU - Goldstein, Desiree S.

AU - Shen, Sui

AU - DeNardo, Sally J.

PY - 1999/10

Y1 - 1999/10

N2 - Single-agent radioimmunotherapy (RIT) has proven efficacy as a treatment for hematological malignancies, particularly non-Hodgkin's lymphoma. Although promising, RIT has been less effective for solid tumors, in part because they are less radiosensitive. Bone marrow transplantation permits the administration of larger radiopharmaceutical doses, but the results of bone marrow transplantation-supported RIT for solid tumors have been marginal. The purpose of this publication is to provide an overview of promising RIT strategies for solid tumors. It is apparent that combination therapy is required, but optimization of the radiopharmaceutical should be the first step. Metallic radionuclides provide higher tumor radiation doses but not necessarily an improved therapeutic index, that is, the ratio of tumor:normal tissue radiation doses. Biodegradable peptide linkers between the chelated metal and the antibody improve the therapeutic index. Further improvements depend on identification of synergistic therapies which recognize that: (a) continuous, low-dose radionuclide therapy acts through apoptosis; and (b) apoptosis is often blocked because most tumors have ineffective p53 and increased Bcl-2. Taxanes are particularly attractive as synergistic agents for RIT because they induce cell cycle arrest in the radiosensitive G2-M phase and p53-independent apoptosis. Optimal sequence and timing for combined modality RIT are critical to achieve synergy. Data from preclinical and clinical studies will be reviewed to illustrate the potential of these strategies.

AB - Single-agent radioimmunotherapy (RIT) has proven efficacy as a treatment for hematological malignancies, particularly non-Hodgkin's lymphoma. Although promising, RIT has been less effective for solid tumors, in part because they are less radiosensitive. Bone marrow transplantation permits the administration of larger radiopharmaceutical doses, but the results of bone marrow transplantation-supported RIT for solid tumors have been marginal. The purpose of this publication is to provide an overview of promising RIT strategies for solid tumors. It is apparent that combination therapy is required, but optimization of the radiopharmaceutical should be the first step. Metallic radionuclides provide higher tumor radiation doses but not necessarily an improved therapeutic index, that is, the ratio of tumor:normal tissue radiation doses. Biodegradable peptide linkers between the chelated metal and the antibody improve the therapeutic index. Further improvements depend on identification of synergistic therapies which recognize that: (a) continuous, low-dose radionuclide therapy acts through apoptosis; and (b) apoptosis is often blocked because most tumors have ineffective p53 and increased Bcl-2. Taxanes are particularly attractive as synergistic agents for RIT because they induce cell cycle arrest in the radiosensitive G2-M phase and p53-independent apoptosis. Optimal sequence and timing for combined modality RIT are critical to achieve synergy. Data from preclinical and clinical studies will be reviewed to illustrate the potential of these strategies.

UR - http://www.scopus.com/inward/record.url?scp=0032697131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032697131&partnerID=8YFLogxK

M3 - Article

C2 - 10541367

AN - SCOPUS:0032697131

VL - 5

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10 SUPPL.

ER -